Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand
1. Incyte's Q2 revenue reached $1.22 billion, beating expectations. 2. The company raised Jakafi's revenue guidance for 2025 to $3 billion. 3. Opzelura revenue grew 35%, reflecting increased patient demand. 4. Recent FDA approval for Monjuvi expands market opportunities. 5. Concerns remain around Jakafi's loss of exclusivity in 2028.